Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, fostemsavir (Rukobia®), in combination with other antiretrovirals, cannot be endorsed for use within NHS Wales for treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen. |
||
|
||
Medicine details |
||
| Medicine name | fostemsavir (Rukobia®) | |
| Formulation | 600 mg prolonged release tablet | |
| Reference number | 2888 | |
| Indication | In combination with other antiretrovirals for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen |
|
| Company | ViiV Healthcare UK Ltd | |
| BNF chapter | Infections | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 23/07/2021 | |